Evidence map›Paper›PMID 32001678›Full record

ArticleNature communications2020

Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection.

Valeria Barili, Paola Fisicaro, Barbara Montanini, Greta Acerbi, Anita Filippi, Giovanna Forleo, Chiara Romualdi, Manuela Ferracin, Francesca Guerrieri, Giuseppe Pedrazzi and 14 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Advances in Lipid Metabolism Reprogramming in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. CAR T cell engineering impacts antigen-independent activation and co-inhibition.Molecular therapy. Methods & clinical development · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Oncolytic avian reovirus-sensitized tumor infiltrating CD8Cell communication and signaling : CCS · 2024
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 2 countries.

Valeria BariliDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Paola FisicaroUnit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Barbara MontaniniBiomolecular, Genomic and Biocomputational Sciences Unit, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.ORCID http://orcid.org/0000-0002-5419-7975
Greta AcerbiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Anita FilippiUnit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Giovanna ForleoUnit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Chiara RomualdiDepartment of Biology, University of Padova, Padova, Italy.
Manuela FerracinDepartment of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy.ORCID http://orcid.org/0000-0002-1595-6887
Francesca GuerrieriCancer Research Center of Lyon (CRCL)-INSERM U1052, Lyon, France.ORCID http://orcid.org/0000-0002-2021-4394
Giuseppe PedrazziUnit of Neuroscience, Department of Medicine and Surgery, Robust Statistics Academy (Ro.S.A.), University of Parma, Parma, Italy.ORCID http://orcid.org/0000-0002-5971-2040
Carolina BoniUnit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Marzia RossiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Andrea VecchiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Amalia PennaUnit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Alessandra ZeccaUnit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Cristina MoriUnit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Alessandra OrlandiniUnit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Elisa NegriUnit of Infectious Diseases and Hepatology, Laboratory of Viral Immunopathology, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
Marco PesciDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Marco MassariUnit of Infectious Diseases, IRCCS-Azienda Ospedaliera S. Maria Nuova, Reggio Emilia, Italy.ORCID http://orcid.org/0000-0003-4234-1973
Gabriele MissaleDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Massimo LevreroCancer Research Center of Lyon (CRCL)-INSERM U1052, Lyon, France.
Simone OttonelloBiomolecular, Genomic and Biocomputational Sciences Unit, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.
Carlo FerrariDepartment of Medicine and Surgery, University of Parma, Parma, Italy. carlo.ferrari@unipr.it.
University of Parma · ITOspedale di Parma · ITAzienda Ospedaliera S.Maria · ITInserm · FRUniversité Claude Bernard Lyon 1 · FRUniversity of Bologna · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus infection (HCV) represents a unique model to characterize, from early to late stages of infection, the T cell differentiation process leading to exhaustion of human CD8+ T cells. Here we show that in early HCV infection, exhaustion-committed virus-specific CD8+ T cells display a marked upregulation of transcription associated with impaired glycolytic and mitochondrial functions, that are linked to enhanced ataxia-telangiectasia mutated (ATM) and p53 signaling. After evolution to chronic infection, exhaustion of HCV-specific T cell responses is instead characterized by a broad gene downregulation associated with a wide metabolic and anti-viral function impairment, which can be rescued by histone methyltransferase inhibitors. These results have implications not only for treatment of HCV-positive patients not responding to last-generation antivirals, but also for other chronic pathologies associated with T cell dysfunction, including cancer.

Indexed as

Acute DiseaseAdolescentAdultAgedAntiviral AgentsAtaxia Telangiectasia Mutated ProteinsCD8-Positive T-LymphocytesChronic DiseaseEpigenesis, GeneticGene Expression ProfilingGene Regulatory NetworksGlucoseHepatitis CHistone MethyltransferasesHumansLymphocyte ActivationAntiviral AgentsAtaxia Telangiectasia Mutated ProteinsGlucoseHistone MethyltransferasesTumor Suppressor Protein p53

Identifiers

PMID32001678
PMCPMC6992697
OpenAlexW3003220126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.